PISCATAWAY, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today presented updated data from clinical and preclinical studies of four investigational messenger RNA (mRNA) antagonists based on the company’s locked nucleic acid (LNA) technology platform, licensed from Santaris A/S. The data were presented in poster sessions at the American Association for Cancer Research 102nd Annual Meeting, which is being held April 2-6, 2011 in Orlando, Florida.
